[Acpc-l] [SPAM?] [MEDIUM] HEALTH CARE SECTOR: NEWS On Tubercin and FDA Testing--Rkeber 03919529

Thu, 12 Feb 2004 19:23:37 -0500

--6199359041279966565
Content-Type: text/plain; charset=us-ascii
Content-Transfer-Encoding: 8bit

protect toss pressure stew scorn relate travail 
derate slop wilfred demigod astigmat inelastic 
caviness birch trance cagey condemnatory 

--6199359041279966565
Content-Type: text/html; charset=us-ascii
Content-Transfer-Encoding: 8bit

Business Wire---Hard to Treat Diseases 
Incorporated - HTDS - Announces: Meeting with T-19 Manufacturer and Tubercin FDA 
Testing
Hard to Treat Diseases Incorporated (Pink Sheets: HTDS) 
announces that consultants of the Company are meeting with a P-3 
manufacturer and an FDA testing group this week. It is expected that a decision 
will be made sometime this month regarding the most expeditious manner to safely 
make available T-19(R) to the people who need it. 
HTDS consultants are also meeting with representatives of a 
prestigious FDA approved testing facility located at a major US University to 
discuss the protocols, procedures, budgets and cost estimates for additional 
testing. The testing results to date have been provided by Dr. Richard Ishmael, 
M.D. of The Natcel, Dev. and Cancer Treatment Center of Oklahoma and Dr. Wei R. 
Chen, Ph.D. of The University of Oklahoma. Such results are currently being 
reviewed by the Company's Scientific Advisory Panel.
HTDS consultants are also meeting with an FDA approved P-3 
manufacturer regarding T-19(R). A P-3 manufacturer is capable of producing a 
product under extreme conditions. Tubercin(R) and the related T-19(R) are 
produced from live Tuberculosis cells under extremely stringent conditions. 
Depending on the approval process required by the testing facility and the 
opinion of the Company's Scientific Advisory Panel, the delivery system for the 
T-19 will either be a nasal spray or an inhaler. 
&quot;The holistic market for T-19(R) as an immunostimulant has phenomenal 
potential,&quot; stated the President and CEO of HTDS, Mr. Colm J. King. &quot;We intend 
to get T-19(R) on the market as fast as possible. Additionally, the Company 
hopes to meet all criteria so that it may qualify Tubercin(R) for fast track 
treatment and thereby deliver it to patients in the near future. Results of the 
above meetings among the consultants will be released when available.&quot; 
Statements in this press release that are not historical facts 
are forward-looking statements within the meaning of the Securities Act of 1933, 
as amended. Those statements include statements regarding the intent, belief or 
current expectations of the Company and its management. Such statements reflect 
management's current views, are based on certain assumptions and involve risks 
and uncertainties. Actual results, events, or performance may differ materially 
from the above forward-looking statements due to a number of important factors, 
and will be dependent upon a variety of factors, including, but not limited to, 
our ability to obtain additional financing and access funds from our existing 
financing arrangements that will allow us to continue our current and future 
operations and whether demand for our product and testing service in domestic 
and international markets will continue to expand. The Company undertakes no 
ob.ligation to publicly update these forward-looking statements to reflect 
events or circumstances that occur after the date hereof or to reflect any 
change in the Company's expectations with regard to these forward-looking 
statements or the occurrence of unanticipated events. 
ebony harlan airspeed ambling whatnot poi mira complainant erik asiatic dodecahedra cartwheel jilt novel sandia bemuse increasable evolve abelson burke priam whitcomb expend pagan picky ahmedabad ammerman arrow except frigate trickery seventy barbados cigarette anhydride educable vent hex e.g carpet bumptious dutch miami annal monocular alcohol diurnal staple mosaic downtrodden peasant armonk avert cotangent railbird isotope potential carbonate flowery oslo styrofoam soulful bacterial competitive tray goldfinch diffract neolithic dub usc disparage boeing subtracter persimmon categoric deathbed breathtaking granola rosenzweig avoid lovebird proprietary illogic glaucous arcadia gunflint hireling drive horntail aloof financier lip marijuana imbrium icon lubricity senegal guinea riggs ti banshee hesitant facet nearsighted butyrate nut borne bulb wean green solidify felice prolix evansville protocol sushi deneb hurrah piston loggerhead

--6199359041279966565--